From 2011 to 2019, pembrolizumab was the only first-line check-point inhibitor available for use in the Czech Republic for patients with a stage IV NSCLC with PD-L1 expression of ˃50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.